These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 12450702)
1. Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Edelman R; Wasserman SS; Kublin JG; Bodison SA; Nardin EH; Oliveira GA; Ansari S; Diggs CL; Kashala OL; Schmeckpeper BJ; Hamilton RG Vaccine; 2002 Dec; 21(3-4):269-80. PubMed ID: 12450702 [TBL] [Abstract][Full Text] [Related]
2. Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Kublin JG; Lowitt MH; Hamilton RG; Oliveira GA; Nardin EH; Nussenzweig RS; Schmeckpeper BJ; Diggs CL; Bodison SA; Edelman R Vaccine; 2002 Mar; 20(13-14):1853-61. PubMed ID: 11906775 [TBL] [Abstract][Full Text] [Related]
3. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara. Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237 [TBL] [Abstract][Full Text] [Related]
4. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. Stoute JA; Slaoui M; Heppner DG; Momin P; Kester KE; Desmons P; Wellde BT; Garçon N; Krzych U; Marchand M N Engl J Med; 1997 Jan; 336(2):86-91. PubMed ID: 8988885 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys. Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW Malar J; 2016 Mar; 15():159. PubMed ID: 26975721 [TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic. El Sahly HM; Patel SM; Atmar RL; Lanford TA; Dube T; Thompson D; Sim BK; Long C; Keitel WA Clin Vaccine Immunol; 2010 Oct; 17(10):1552-9. PubMed ID: 20702657 [TBL] [Abstract][Full Text] [Related]
7. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466 [TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial. Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O; Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345 [TBL] [Abstract][Full Text] [Related]
9. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. Wizel B; Houghten RA; Parker KC; Coligan JE; Church P; Gordon DM; Ballou WR; Hoffman SL J Exp Med; 1995 Nov; 182(5):1435-45. PubMed ID: 7595214 [TBL] [Abstract][Full Text] [Related]
10. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Malkin EM; Diemert DJ; McArthur JH; Perreault JR; Miles AP; Giersing BK; Mullen GE; Orcutt A; Muratova O; Awkal M; Zhou H; Wang J; Stowers A; Long CA; Mahanty S; Miller LH; Saul A; Durbin AP Infect Immun; 2005 Jun; 73(6):3677-85. PubMed ID: 15908397 [TBL] [Abstract][Full Text] [Related]
11. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice. Mata E; Carcaboso AM; Hernández RM; Igartua M; Corradin G; Pedraz JL Vaccine; 2007 Jan; 25(5):877-85. PubMed ID: 17070628 [TBL] [Abstract][Full Text] [Related]
13. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. Hoffman SL; Edelman R; Bryan JP; Schneider I; Davis J; Sedegah M; Gordon D; Church P; Gross M; Silverman C Am J Trop Med Hyg; 1994 Nov; 51(5):603-12. PubMed ID: 7985753 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cells. Herrington DA; Losonsky GA; Smith G; Volvovitz F; Cochran M; Jackson K; Hoffman SL; Gordon DM; Levine MM; Edelman R Vaccine; 1992; 10(12):841-6. PubMed ID: 1455910 [TBL] [Abstract][Full Text] [Related]